Literature DB >> 3364161

Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease.

N G Conradi1, H Kalimo, P Sourander.   

Abstract

Splenectomy in children with the Norrbottnian type of Gaucher disease is followed by increased blood levels of glucosylceramide and impaired neurological and mental status. High blood levels are associated with an increased accumulation of glucosylceramide in perivascular Gaucher cells in the brain compared to non-splenectomised cases. Surrounding the Gaucher cell infiltrates there is loss of neurons and slight demyelination in the brain parenchyma. The brains of four cases with the Norrbottnian type of Gaucher disease were examined by immunohistochemical stains in an attempt to further characterize the perivascular Gaucher cells and to examine the reactions of the vessel walls and brain parenchyma to the accumulation of Gaucher cells. The perivascular storage cells showed granular staining with antibodies to muramidase and alpha 1-anti-chymotrypsin confirming that they are blood-derived macrophages belonging to the monocyte-macrophage system. The Gaucher cells contained material positive for antisera to plasma proteins strongly suggesting that large molecules (including glucosylceramide) can escape from the blood and be taken up by the macrophages in Gaucher disease. The storage cells were surrounded by a reticulin network stained by antisera to collagen type III, type IV and laminin. The infiltrates were bounded from the brain parenchyma by a membrane strongly positive with antiserum for the basal lamina protein collagen type IV and laminin. The formation of a basal lamina around the Gaucher cell cuffs probably constitutes a protective phenomenon governing the brain parenchyma against the foreign cells. A focal loss of neurons but only minor loss of axons could be demonstrated with the antiserum to neurofilament.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3364161     DOI: 10.1007/bf00687792

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  16 in total

1.  Experimental studies on the pathogenesis of leucodystrophies. II. The effect of sphingolipids on various cell types in cultures from the nervous system.

Authors:  P Sourander; H A Hansson; Y Olsson; L Svennerholm
Journal:  Acta Neuropathol       Date:  1966-06-01       Impact factor: 17.088

2.  The origin of brain macrophages in traumatic lesions, Wallerian degeneration, and retrograde degeneration.

Authors:  A E Stenwig
Journal:  J Neuropathol Exp Neurol       Date:  1972-10       Impact factor: 3.685

3.  Monocytes become macrophages; they do not become microglia: a light and electron microscopic autoradiographic study using 125-iododeoxyuridine.

Authors:  R L Schelper; E K Adrian
Journal:  J Neuropathol Exp Neurol       Date:  1986-01       Impact factor: 3.685

4.  Gaucher disease--Norrbottnian type. Neurodevelopmental, neurological, and neurophysiological aspects.

Authors:  S Blom; A Erikson
Journal:  Eur J Pediatr       Date:  1983-09       Impact factor: 3.183

5.  Gaucher disease--Norrbottnian type. I. General clinical description.

Authors:  S Dreborg; A Erikson; B Hagberg
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

6.  Fine structure of central nervous system in early infantile Gaucher's disease.

Authors:  M Adachi; B J Wallace; L Schneck; B W Volk
Journal:  Arch Pathol       Date:  1967-06

7.  Characterization of the perivascular reticulin network in a case of primary brain lymphoma. Immunohistochemical demonstration of collagen types I, III, IV, and V; laminin; and fibronectin.

Authors:  H Kalimo; M Lehto; K Näntö-Salonen; M Jalkanen; L Risteli; J Risteli; E V Narva
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III.

Authors:  O Nilsson; G Håkansson; S Dreborg; C G Groth; L Svennerholm
Journal:  Clin Genet       Date:  1982-11       Impact factor: 4.438

9.  Neutral proteinases secreted by macrophages degrade basic protein: a possible mechanism of inflammatory demyelination.

Authors:  W T Norton; W Cammer; B R Bloom; S Gordon
Journal:  Adv Exp Med Biol       Date:  1978       Impact factor: 2.622

10.  Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies.

Authors:  N G Conradi; P Sourander; O Nilsson; L Svennerholm; A Erikson
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

View more
  12 in total

Review 1.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

2.  Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.

Authors:  M Elleder
Journal:  J Inherit Metab Dis       Date:  2006-11-02       Impact factor: 4.982

3.  Cauda equina syndrome due to an intra-dural sacral cyst in type-1 Gaucher disease.

Authors:  Abderrahmane Hamlat; Stephan Saikali; Mohamed Lakehal; Michèle Pommereuil; Xavier Morandi
Journal:  Eur Spine J       Date:  2003-12-20       Impact factor: 3.134

4.  CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.

Authors:  Thomas A Burrow; Ying Sun; Carlos E Prada; Laurie Bailey; Wujuan Zhang; Amanda Brewer; Steve W Wu; Kenneth D R Setchell; David Witte; Mitchell B Cohen; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2014-09-02       Impact factor: 4.797

5.  Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process.

Authors:  H Hůlková; J Ledvinová; H Poupetová; A Kohout; V Malinová; M Elleder
Journal:  J Inherit Metab Dis       Date:  2009-06-26       Impact factor: 4.982

6.  Pharmacotherapy of Gaucher Disease: Current and Future Options.

Authors:  Lunawati L Bennett; Chris Fellner
Journal:  P T       Date:  2018-05

Review 7.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

8.  Optimal therapy in Gaucher disease.

Authors:  Ozlem Goker-Alpan
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

9.  Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.

Authors:  Ying Sun; Benjamin Liou; Huimin Ran; Matthew R Skelton; Michael T Williams; Charles V Vorhees; Kazuyuki Kitatani; Yusuf A Hannun; David P Witte; You-Hai Xu; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2010-01-04       Impact factor: 6.150

10.  Defective Self-Renewal and Differentiation of GBA-Deficient Neural Stem Cells Can Be Restored By Macrophage Colony-Stimulating Factor.

Authors:  Hyun Lee; Jae-sung Bae; Hee Kyung Jin
Journal:  Mol Cells       Date:  2015-08-18       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.